Article and Video CATEGORIES

Cancer Journey

Search By

Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC
Author
GRACE Videos and Articles

Camidge_Ceritinib_Second_Generation_ALK_Inhibitors_Acquired_Resistance_ALK-Positive_NSCLC

 

Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.

 

 

Transcript

One of the exciting things about the ALK field is that in a relatively short space of time, we’ve gone from defining a molecular subtype of lung cancer that responds very nicely to a first generation drug, crizotinib, that we’ve actually not got more choices. More specific, more potent ALK inhibitors have been developed: ceritinib, alectinib, brigatinib to name a few. Ceritinib is already licensed — the other two drugs have got what’s called FDA breakthrough approval. That means the FDA is very keep to look at the results, and hopefully if they’re good, will license the drug fairly quickly.

What they’re showing is, one: because they tend to be slightly cleaner drugs, they have a different side effect profile from crizotinib. For example they tend to not have the swelling of the ankles and other areas of swelling which is associated with an off target effect of crizotinib called anti-MET activity. However they’re not completely free from side effects. Ceritinib for example has a lot of gastrointestinal side effects — a lot of nausea, a lot of vomiting and diarrhea, and nearly 60% of people need a dose reduction. The alectinib and brigatinib are looking relatively cleaner in terms of the side effects.

In terms of whether they work: after the crizotinib has stopped working, people have progressed in one of two ways. Either their cancer is growing in their brain because crizotinib doesn’t penetrate into the brain very well, or the cancer has evolved and changed its biology in the presence of the crizotinib.

The good news is these next generation drugs work on both of those mechanisms. Either more is getting into the brain or the drug is just more potent, and therefore we’re seeing responses in the brain, and also they work on some of the known resistance mechanisms to crizotinib. We’re seeing 50-70% of people responding in their body after initially progressing on crizotinib.

So very rapidly we now have a clearly defined next line of therapy for ALK-positive patients progressing on crizotinib.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Blood Cancers OncTalk 2024
Video
  This event was moderated by Dr. Sridevi Rajeeve, Memorial Sloan Kettering, joined by speakers: Dr. Hamza Hashmi, Memorial Sloan Kettering, Dr. Michele Stanchina, University of Miami, Dr. Muhammad Salman Faisal, Oklahoma University, and Dr. Andrew Srisuwananukorn, Ohio State University Topics include: - Myeloma 101: Facts and Fiction of the 'Myeloma Marathon' - Updates in DLBCL - Treatment Basics of Bone Marrow Transplant - Frontline Therapies in Myelofibrosis - Panel Discussions and a Question-and-Answer session
Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.

Forum Discussions

Hi Stan,

It's so good to hear you and yours are doing well and that you were able to spend time with both families for Thanksgiving.  I know it meant a...

Hi Stan!  It is good to hear from you -- I am so very happy you are doing well.  I agree with Janine that family and friends - our chosen family...

Recent Comments

JOIN THE CONVERSATION
So good to hear from you Stan
By dbrock on
Hi Stan,

It's so good to…
By JanineT GRACE … on
I could not find any info on…
By JanineT GRACE … on